Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pacira BioSciences's change in inventory for the quarter that ended in Mar. 2026 was €2.2 Mil. It means Pacira BioSciences's inventory
declined by €2.2 Mil
from Dec. 2025 to Mar. 2026 .
Pacira BioSciences's change in inventory for the fiscal year that ended in Dec. 2025 was €-23.5 Mil. It means Pacira BioSciences's inventory
increased by €23.5 Mil
from Dec. 2024 to Dec. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Pacira BioSciences's Days Inventory for the quarter that ended in Mar. 2026 was 377.51.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Pacira BioSciences's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.24.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Pacira BioSciences's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.85.
Pacira BioSciences (FRA:82P) Change In Inventory Explanation
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Pacira BioSciences's Days Inventory for the quarter that ended in is calculated as:
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Pacira BioSciences's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences Change In Inventory Related Terms
Pacira BioSciences Change In Inventory Historical Data
* Premium members only.
The historical data trend for Pacira BioSciences's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences Change In Inventory Calculation
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-14.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of €-14.3 Mil mean?
Pacira BioSciences (FRA:82P) has a Change In Inventory of €-14.3 Mil as of Mar. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Pacira BioSciences and its competitors.
Is Pacira BioSciences' Change In Inventory too high?
Pacira BioSciences' current Change In Inventory is €-14.3 Mil. Overall, Pacira BioSciences has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Change In Inventory compare to ALVO and BIOA?
Pacira BioSciences' Change In Inventory of €-14.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Drug Manufacturers company?
A good Change In Inventory depends on the Drug Manufacturers industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Pacira BioSciences and its competitors. Pacira BioSciences's current Change In Inventory is €-14.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current Change In Inventory of €-14.3 Mil. The stock's GF Value™ is €25.59, compared to a current price of €22.20 — trading 13.2% below its estimated fair value. The current Change In Inventory is €-14.3 Mil. Pacira BioSciences' overall GF Score™ is 82/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current Change In Inventory is €-14.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacira BioSciences (FRA:82P) Overvalued in 2026?
Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued.
The current stock price of €22.20 is trading 13.2% below its estimated GF Value™ of €25.59.
Key valuation signals for FRA:82P:
Change In Inventory: €-14.3 Mil
GF Value™: €25.59 vs. price of €22.20 (13.2% below fair value)
No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
82GF Score
Get the complete analysis for FRA:82P
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:82P has been successfully added to your 
